Did Gilead Aid the Hit Job against HCQ?

2020-04-27 update: Yes, it did. Most members of the COVID-19 Treatment Panel had ties to Gilead.

Gilead Sciences (GILD, market cap 104B) is the manufacturer and owner of patents for Remdesivir. Remdesivir is competing with hydroxychloroquine (HCQ) as a COVID-19 treatment, although more expensive, less tested, and, apparently, less efficient. HCQ is a generic drug with very low profit margins.

9 out of 50 members on the Panel for COVID-19 Treatment Guidelines disclosed that they had financial ties to Gilead from May 1, 2019, to March 31, 2020. The  reporting period surprisingly covered only 10 short months, and ended three weeks before publication of the report.`So any financial ties (and there are many) that predated this 10 month period, were not disclosed.

Also, let’s look at how flattering the fake news media and Google are to Gilead and  Remdesivir:

and compare this with the coverage of HCQ:

All searches performed  in a browser with a clean state, in Texas, on April 23, at approximately 11 am.

More Screenshots

Leave a Reply

Your email address will not be published. Required fields are marked *